At the news
? NEUTRALIMPACT 4/10 8-K filed Jun 15, 2026 at 16:35 ET
Vistagen reported fiscal year 2026 financial results with net loss widening to $69.7M and cash at $45.4M, while providing pipeline updates including the imminent PALISADE-4 Phase 3 topline readout for fasedienol in social anxiety disorder. The filing is a routine pre-revenue biotech earnings update with no financial surprises; the stock will move on the binary PALISADE-4 results expected this month.
- Total revenues for FY2026 were $1.269M (sublicense and other), up from $0.486M in FY2025.
- Net loss was $69.685M for FY2026, compared to $51.418M in FY2025.
- Cash, cash equivalents, and marketable securities were $45.4M as of March 31, 2026, sufficient to fund operations into 2027.
- PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder: randomized portion completed, topline results expected in June 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access